111, China-based online drugstore and healthcare platform, sets US IPO range to $14-$16/share, will raise $140M at $1.5B valuation at the midpoint of the range
NASDAQ.com :
Context & Ripple Effects
111's listing lands mid-wave in a 2018 run of China-to-US consumer platform IPOs: weeks earlier, Pinduoduo priced at the top of its range, raising $1.63B at a $23.8B valuation, while online-healthcare rival WeDoctor had already banked a $500M private round at a $5.5B valuation with an IPO flagged for the same year.
The contrast matters: at a $140M raise and $1.5B midpoint, 111 is an order of magnitude smaller than both, making it a test of whether US appetite for Chinese healthcare platforms extends below the mega-deal tier.
First-order effects
- 111's existing backers see their stake priced against WeDoctor's $5.5B private mark, forcing a direct public-market comparison between the two China online-healthcare platforms.
- A successful pricing gives 111 roughly $140M of new capital for its online drugstore and healthcare business while it remains far smaller than its best-funded domestic competitor.
Second-order effects
- Where 111 prices within or below its $14–$16 range becomes a demand read for the next tier of Chinese consumer-platform listings, after Pinduoduo's high-end print set the bullish benchmark.
- WeDoctor's own planned IPO now has a public comp: if 111 trades at a steep discount to WeDoctor's private valuation, the larger platform's pricing power in the same window weakens.
Third-order effects
- If mid-size China health-tech listings keep clearing at $1–2B valuations, US exchanges consolidate their role as the default exit for Chinese online healthcare, tiering the sector into mega-platforms and sub-$200M raises rather than a single valuation band.
The trend: Chinese online healthcare and consumer platforms are routing their exits through US IPOs, with deal sizes splitting into a mega tier (Pinduoduo, WeDoctor) and a mid tier (111) that tests how deep Western demand runs.